Acrivon Therapeutics, Inc. (ACRV) Free cash flow 2021–2025
Acrivon Therapeutics, Inc. (ACRV) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$65.3MFY2025 · since FY2021: -$14.2M → -$65.3M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$65.3M | +4.5% |
| FY2024 | -$68.4M | -55.8% |
| FY2023 | -$43.9M | -36.1% |
| FY2022 | -$32.3M | -127.0% |
| FY2021 | -$14.2M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More ACRV financial trends
ACRV RevenueACRV Net incomeACRV Net marginACRV Gross profitACRV Gross marginACRV Operating incomeACRV Operating marginACRV Operating cash flowACRV Capital expendituresACRV Return on equityACRV Stock buybacksACRV Dividends paidACRV Total assetsACRV Total liabilitiesACRV Shareholders’ equityACRV overview →